Free Trial

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Xenon Pharmaceuticals logo
$38.82 -0.05 (-0.13%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Key Stats

Today's Range
$38.71
$39.24
50-Day Range
$30.30
$38.87
52-Week Range
$26.74
$46.00
Volume
46,795 shs
Average Volume
885,104 shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.20
Consensus Rating
Buy

Company Overview

Xenon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

XENE MarketRank™: 

Xenon Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 674th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Xenon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.76) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xenon Pharmaceuticals is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xenon Pharmaceuticals is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xenon Pharmaceuticals has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Xenon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.47% of the float of Xenon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Xenon Pharmaceuticals has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xenon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Xenon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.47% of the float of Xenon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Xenon Pharmaceuticals has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xenon Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Xenon Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    6 people have searched for XENE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91.00 in company stock.

  • Percentage Held by Insiders

    Only 4.07% of the stock of Xenon Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xenon Pharmaceuticals' insider trading history.
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XENE Stock News Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
FY2025 Earnings Estimate for XENE Issued By Chardan Capital
TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)
Xenon Completes Patient Recruitment for Phase 3 Study
See More Headlines

XENE Stock Analysis - Frequently Asked Questions

Xenon Pharmaceuticals' stock was trading at $39.20 at the start of the year. Since then, XENE stock has decreased by 0.8% and is now trading at $38.87.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Monday, August, 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.04.
Read the conference call transcript
.

Xenon Pharmaceuticals' top institutional shareholders include Braidwell LP (4.68%), Commodore Capital LP (3.92%), Vestal Point Capital LP (2.59%) and Holocene Advisors LP (2.35%). Insiders that own company stock include Ian Mortimer, Dawn Svoronos, Gary Patou, Sherrington Robin, Steven Gannon, Simon N Pimstone, Christopher John Kenney and Sherry Aulin.
View institutional ownership trends
.

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/11/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XENE
CIK
1582313
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$67.00
Low Price Target
$43.00
Potential Upside/Downside
+36.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$234.33 million
Net Margins
N/A
Pretax Margin
-3,767.93%
Return on Equity
-38.50%
Return on Assets
-36.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.14
Quick Ratio
15.14

Sales & Book Value

Annual Sales
$9.43 million
Price / Sales
317.84
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.22 per share
Price / Book
4.73

Miscellaneous

Outstanding Shares
77,110,000
Free Float
73,968,000
Market Cap
$3.00 billion
Optionable
Optionable
Beta
1.16

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:XENE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners